Summary of Study ST000414

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000323. The data can be accessed directly via it's Project DOI: 10.21228/M8ZS3N This work is supported by NIH grant, U2C- DK119886.


Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST000414
Study TitleMetabolomics-based screening of the Malaria Box reveals both novel and established mechanisms of action
Study TypeDrug incubation
Study SummaryMeasuring the impact of MMV Malaria Box compounds on metabolism in Plasmodium falciparum-infected red blood cells
Monash Institute of Pharmaceutical Sciences
DepartmentDrug delivery, disposition and dynamics
LaboratoryCreek lab
Last NameCreek
First NameDarren
Address381 Royal Parade, Parkville, Melbourne, VIC3052, Australia
Submit Date2016-06-16
Num Groups126
Total Subjects18
Study Comments524
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2017-07-10
Release Version1
Darren Creek Darren Creek application/zip

Select appropriate tab below to view additional metadata details:


Treatment ID:TR000449
Treatment Summary:Cultures (200 µL) were incubated with test compounds (1 µM) for 5 hours in 96-well plates. Four replicate incubations of each compound were conducted and analyzed. Untreated controls contained equivalent amounts of DMSO (as vehicle), and additional ‘quench test’ controls were prepared whereby the test compounds were added after the quenching step, to allow detection of test compound-derived LC-MS features that did not arise from biochemical metabolism within the cells. Each plate contained 10 or 20 test compounds in addition to positive controls (artemisinin and/or atovaquone) and negative controls (untreated DMSO and ‘quench test’ described above). Incubations and extractions for the 100 test compounds (10 compounds with known antimalarial activity and 90 of the highest priority compounds from the Malaria Box including all of plate A and the first row of plate B) were performed in three separate batches, with the known antimalarial compounds and first 10 Malaria Box compounds in the first batch, the next 40 Malaria Box compounds in the second batch, and the following 40 Malaria Box compounds in the third batch.
Treatment Compound:Antimalarials and MMV Malaria Box compounds
Treatment Dose:1 micromolar
Treatment Doseduration:5 hours
Treatment Vehicle:DMSO
Cell Growth Container:96-well V-bottomed plate
Cell Envir Cond:37 °C under defined atmosphere (95% N2, 4% CO2, 1% O2)
Cell Media Lastchanged:18 hours